Ferring Pharmaceuticals agreed to acquire Gameto in a deal valued at up to $1.38 billion, bringing a cell-engineering fertility platform into Ferring’s pipeline strategy. The transaction signals continuing consolidation around gamete and reproductive cell technologies as developers look for faster scale-up and clinical execution.